Denali Therapeutics Inc (NAS:DNLI)
$ 20.61 -0.71 (-3.33%) Market Cap: 2.97 Bil Enterprise Value: 2.28 Bil PE Ratio: 0 PB Ratio: 2.25 GF Score: 57/100

Denali Therapeutics Inc at Stifel CNS Days (Virtual) Transcript

Mar 29, 2022 / 02:00PM GMT
Release Date Price: $34.47 (+4.45%)
Paul Matteis
Stifel Nicolaus - Analyst

Great, thank you very much. It's always a pleasure to be moderating a panel with Ryan Watts, CEO and Founder of Denali. Obviously you have a ton going on at Denali as well. So, maybe, Ryan, sort of give a quick overview and update on your various key programs and then we can make it more conversational. So, thank you again.

Ryan Watts
Denali Therapeutics Inc. - CEO

Thanks again for the invitation. I think this is the third or fourth year in a row that I have been at a CNS day and what an interesting time to have a CNS day and to talk about an enormous unmet need with Alzheimer's, Parkinson's, ALS. In the case of Denali, we also go after some rare neurodegenerative diseases or diseases that have neurodegenerative components such as lysosomal storage diseases.

And I think it's an exciting time, it's a challenging area, no doubt. And for us, we've approached it really with three principles. So, for us the first principle is what we call the degenogene pathway. So, genes when mutated that cause neurodegeneration.

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot